WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H414002
CAS#: 480449-71-6 (tosylate)
Description: Edoxaban tosylate is a prophylaxis of Thromboembolic Complications Associated with Atrialfibrillation, Treatment and Prevention of VTE
Hodoodo Cat#: H414002
Name: Edoxaban tosylate
CAS#: 480449-71-6 (tosylate)
Chemical Formula: C31H38ClN7O7S2
Exact Mass: 719.20
Molecular Weight: 720.260
Elemental Analysis: C, 51.70; H, 5.32; Cl, 4.92; N, 13.61; O, 15.55; S, 8.90
Related CAS #: 1229194-11-9 (tosylate hydrate) 480449-71-6 (tosylate) 480448-29-1 (HCl) 480449-70-5 (free base)
Synonym: Edoxaban tosylate; DU176b; DU-176b; DU 176b
IUPAC/Chemical Name: N-(5-Chloropyridin-2-yl)-N'-((1S,2R,4S)-4-(N,N-dimethylcarbamoyl)-2-(5-methyl-4,5,6,7- tetrahydro(1,3)thiazolo(5,4-c)pyridine-2-carboxamido)cyclohexyl)oxamide, 4- methylbenzenesulfonate
InChi Key: ZLFZITWZOYXXAW-QXXZOGQOSA-N
InChi Code: InChI=1S/C24H30ClN7O4S.C7H8O3S/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23;1-6-2-4-7(5-3-6)11(8,9)10/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34);2-5H,1H3,(H,8,9,10)/t13-,15-,17+;/m0./s1
SMILES Code: O=C(NC1=NC=C(Cl)C=C1)C(N[C@@H]2[C@H](NC(C(S3)=NC4=C3CN(C)CC4)=O)C[C@@H](C(N(C)C)=O)CC2)=O.O=S(C5=CC=C(C)C=C5)(O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 720.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548805/ PubMed PMID: 31644112.
2: Cervantes CE, Merino JL, Barrios V. Edoxaban for the prevention of stroke in patients with atrial fibrillation. Expert Rev Cardiovasc Ther. 2019 Apr;17(4):319-330. doi: 10.1080/14779072.2019.1598263. Epub 2019 Mar 27. Review. PubMed PMID: 30897988.
3: Pharmacoeconomic Review Report: Edoxaban (Lixiana) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK535088/ PubMed PMID: 30540394.
4: CADTH Canadian Drug Expert Committee Final Recommendation: Edoxaban: (Lixiana — Servier Canada Inc.): Indication: Venous Thromboembolic Events [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 May. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK534995/ PubMed PMID: 30540393.
5: Clinical Review Report: Edoxaban (Lixiana) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK535077/ PubMed PMID: 30540391.
6: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK500740/ PubMed PMID: 29999799.
7: Linkins LA MD, MSc, FRCPC. Edoxaban is non-inferior to low-molecular-weight heparin for treating cancer-associated venous thromboembolism. BMJ Evid Based Med. 2018 Dec;23(6):230. doi: 10.1136/bmjebm-2018-111007. Epub 2018 Jun 29. Review. PubMed PMID: 29959155.
8: Edoxaban (Lixiana) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr. Available from http://www.ncbi.nlm.nih.gov/books/NBK475920/ PubMed PMID: 29341555.
9: Institute for Quality and Efficiency in Health Care. Edoxaban -- Benefit Assessment According to §35a Social Code Book V [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2015 Oct 28. Available from http://www.ncbi.nlm.nih.gov/books/NBK458399/ PubMed PMID: 29144699.
10: Hammwöhner M, Goette A. The safety of edoxaban for treating atrial fibrillation. Expert Opin Drug Saf. 2017 Nov;16(11):1295-1303. doi: 10.1080/14740338.2017.1372418. Epub 2017 Sep 18. Review. PubMed PMID: 28862063.
11: O'connor CT, Kiernan TJ, Yan BP. The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). Expert Opin Drug Metab Toxicol. 2017 Jul;13(7):725-739. doi: 10.1080/17425255.2017.1338274. Epub 2017 Jun 13. Review. PubMed PMID: 28571507.
12: Gibson CM, Finks SW. Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape? Am J Med. 2017 Aug;130(8):900-906. doi: 10.1016/j.amjmed.2017.02.048. Epub 2017 Apr 6. Review. PubMed PMID: 28390791.
13: Scheen AJ, Lancellotti P. [Edoxaban (LIXIANA®) : new oral anticoagulant forthetreatment and secondary prevention of thromboembolic disease]. Rev Med Liege. 2016 Nov;71(11):517-524. Review. French. PubMed PMID: 28387109.
14: Weiss TW, Rohla M, Dieplinger B, Domanovits H, Fries D, Vosko MR, Gary T, Ay C. [Edoxaban for stroke prevention in atrial fibrillation and treatment of venous thromboembolism: an expert position paper]. Wien Med Wochenschr. 2018 Apr;168(5-6):133-143. doi: 10.1007/s10354-017-0548-4. Epub 2017 Feb 24. Review. German. PubMed PMID: 28236004.
15: Curto A, Curto D, Sanchez J. Managing patients taking edoxaban in dentistry. J Clin Exp Dent. 2017 Feb 1;9(2):e308-e311. doi: 10.4317/jced.53431. eCollection 2017 Feb. Review. PubMed PMID: 28210454; PubMed Central PMCID: PMC5303336.
16: De Caterina R, Ageno W, Boriani G, Colonna P, Ghirarduzzi A, Patti G, Rossini R, Rubboli A, Schinco P, Agnelli G. Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide. Adv Ther. 2017 Mar;34(3):620-637. doi: 10.1007/s12325-017-0488-9. Epub 2017 Feb 13. Review. PubMed PMID: 28194578; PubMed Central PMCID: PMC5350200.
17: Poulakos M, Walker JN, Baig U, David T. Edoxaban: A direct oral anticoagulant. Am J Health Syst Pharm. 2017 Feb 1;74(3):117-129. doi: 10.2146/ajhp150821. Review. PubMed PMID: 28122753.
18: Aspromonte N, Colivicchi F. Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure. Expert Opin Drug Metab Toxicol. 2017 Jan;13(1):113-122. Epub 2016 Nov 18. Review. PubMed PMID: 27819149.
19: Minguet J, Sims HM, Smith KH, Bramlage P. The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Expert Rev Clin Pharmacol. 2017 Jan;10(1):5-15. doi: 10.1080/17512433.2016.1258301. Epub 2016 Nov 17. Review. Erratum in: Expert Rev Clin Pharmacol. 2017 Jan;10 (1):1. PubMed PMID: 27817212.
20: AlHajri L, Jabbari S, AlEmad H, AlMahri K, AlMahri M, AlKitbi N. The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery: A Systematic Review. J Cardiovasc Pharmacol Ther. 2017 May;22(3):230-238. doi: 10.1177/1074248416675732. Epub 2016 Nov 2. Review. PubMed PMID: 27811198.